July 7, 2017

CMS: Drug and device companies paid providers $8.18B in 2016

Daily Briefing

    Teaching hospitals and physicians received $8.18 billion from drugmakers and medical device manufacturers in 2016, an increase from 2015's total of about $7.5 billion, according to data from CMS' Open Payments database.

    Join the Advisory Board’s supply chain experts on July 25 to discuss the changing GPO landscape

    Background

    CMS launched the Open Payments System—which was required under the Affordable Care Act's Sunshine Act provision—in September 2014. According to the Becker's Hospital Review, drugmakers and medical device manufacturers under the Open Payments program are required to report payments they make to providers and teaching hospitals for beverages, food, licenses, lodging, investments, travel, and research. 

    In making the data public, Healthcare Finance reports, CMS aims to increase transparency about the financial relationships between physicians, teaching hospitals, and manufacturers; identify any wasteful spending; and monitor the influence drugmakers and device manufacturers have on care, education, and research.

    According to Becker's Hospital Review, CMS has also updated the Open Payments website so that visitors can compare specific providers to the national average and to other providers working in the same specialty. Visitors are also able to view payments received by providers in each state.

    Data details

    Overall, the data show that drugmakers and medical device manufacturers made $8.18 billion in payments and ownership or investment interests to nearly 631,000 physicians and 1,149 teaching hospitals.

    Of the $8.18 billion:
    • $4.36 billion went to research, accounting for nearly half of the total;
    • $2.8 billion were non-research-related payments, including drug representative meals, travel expenses, and consulting fees; and
    • $1.02 billion went toward ownership or investment interests.

    When broken down by type of payment, about 80 percent of the payments went toward services, consulting, and royalties, while roughly 20 percent went toward food, beverage, travel, and lodging, according to Healthcare Finance. Specifically, drugmakers and device manufacturers' payments included:

    • About $562 million for services other than consulting;
    • About $490 million for royalty or licensing;
    • About $366 million for consulting fees;
    • About $246 million for food and beverage;
    • About $190 million for travel and lodging;
    • About $24 million in grant money; and
    • About $44 million in honoraria.

    According to Modern Healthcare, providers and hospitals are able to review the data. Currently, physicians and hospitals are disputing only $39 million of the reported total (Dickson, Modern Healthcare, 7/5; Paavola, Becker's Hospital CFO Report, 7/5; Sullivan, Healthcare Finance, 7/5).

    Don't take your price transparency journey alone

    In an increasingly price-sensitive world, you need a top-notch price transparency plan to stay competitive. We estimate that it would take most organizations over 1,000 hours to do this on their own.

    Download our executive briefing to learn why you shouldn’t fly solo when assessing your market and crafting a price transparency plan.

    Get the Briefing

    Have a Question?

    x

    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.

    X
    Cookies help us improve your website experience. By using our website, you agree to our use of cookies.